Compass Therapeutics
gastrointestinal a phase randomized double blind placebo controlled study of in combination with plus in patients with advanced biliary tract cancer topaz | Compass Therapeutics
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
11 of 36
Related slides by other companies
Genelux
Investor Presentation
October 2023
diversified designs and indications exploit competitive advantages bene | Genelux
Genelux
Investor Presentation
July 2023
diversified designs and indications exploit competitive advantages bene | Genelux
Genelux
Investor Presentation
July 2023
completed phase tested published in jama oncology link | Genelux
Genelux
Investor Presentation
December 2023
completed phase tested primed heavily patients with platinum resistant or platinum refractory ovarian cancer published in jama oncology link | Genelux
Other recent decks by Compass Therapeutics
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
February 2023
Investor Presentation
January 2023
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io